Add like
Add dislike
Add to saved papers

Research and commentary.

Background The lack of appropriate available medications for children is a well-known problem. Before a medicine is licensed, has to undergo extensive studies to test safety and efficacy in the target population, however, 50-70 per cent of drugs given to children have not been tested for this specific population. Barriers to research on children's drug development include: cost compared with the size of the market, making it financially unrewarding for pharmaceutical companies; difficulties in trial design; time taken to complete studies; long approval processes; complex ethical considerations; and risk-benefit issues. Doctors frequently rely on their own clinical judgement when weighing up the dilemma of prescribing a medication that has been untested in children against the potential benefits. This article examines the European Paediatric Regulation introduced in 2007 by the European Commission to improve the development of high quality medicines for children aged zero to 17 years through a framework of rewards and incentives for pharmaceutical companies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app